Free Trial
→ Buffett’s Next Move Could Shock Wall Street (From Golden Portfolio) (Ad) Buy COLL Stock  Free COLL Stock Alerts

Collegium Pharmaceutical (COLL) Financials

Collegium Pharmaceutical logo
$29.18 +0.27 (+0.93%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$29.20 +0.02 (+0.07%)
As of 05/29/2025 04:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Collegium Pharmaceutical

Annual Income Statements for Collegium Pharmaceutical

This table shows Collegium Pharmaceutical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Net Income / (Loss) Attributable to Common Shareholders		 69 48 -25 72 27 -23 -39 -75 -94 -27 0.00
Consolidated Net Income / (Loss)		 69 48 -25 72 27 -23 -39 -75 -94 -27 0.00
Net Income / (Loss) Continuing Operations		 69 48 -25 72 27 -23 -39 -75 -94 -27 0.00
Total Pre-Tax Income 		99 76 -29 -3.37 28 -23 -39 -75 -94 -27 0.00
Total Operating Income		 170 167 33 18 56 -24 -21 -75 -94 -27 0.00
Total Gross Profit		 377 326 209 151 180 103 115 26 1.50 0.00 0.00
Total Revenue		 631 567 464 277 310 297 280 28 1.71 0.00 0.00
Operating Revenue		 631 567 464 277 310 297 280 28 1.71 0.00 -
Total Cost of Revenue		 254 241 254 126 130 194 166 2.60 0.21 0.00 0.00
Operating Cost of Revenue		 254 241 254 126 130 194 166 2.60 0.21 0.00 -
Total Operating Expenses		 207 159 176 133 124 127 135 101 96 27 0.00
Selling, General & Admin Expense		 210 159 172 119 114 116 127 93 81 19 -
Research & Development Expense		 0.00 0.00 3.98 9.45 9.77 10 8.66 8.57 15 7.98 -
Other Special Charges / (Income)		 -2.91 0.00 0.00 - 0.00 0.00 - - - - -
Total Other Income / (Expense), net		 -71 -91 -62 -21 -29 1.03 -18 0.58 -0.09 -0.35 0.00
Interest Expense		 85 107 63 21 29 0.91 20 - 0.09 -0.09 -
Interest & Investment Income		 14 16 1.05 0.01 0.23 1.94 1.69 0.58 - -0.44 -
Income Tax Expense		 29 28 -3.85 -75 0.83 0.00 0.00 - - - -
Basic Earnings per Share		 $2.14 $1.43 ($0.74) $2.05 $0.78 ($0.68) ($1.19) ($2.47) ($3.88) ($1.48) ($22.72)
Weighted Average Basic Shares Outstanding		 32.27M 33.74M 33.83M 34.94M 34.41M 33.45M 32.95M 30.27M 24.26M 13.54M 934.00K
Diluted Earnings per Share		 $1.86 $1.29 ($0.74) $1.86 $0.76 ($0.68) ($1.19) ($2.47) ($3.88) ($1.48) ($22.72)
Weighted Average Diluted Shares Outstanding		 40.42M 41.79M 33.83M 41.05M 35.15M 33.45M 32.95M 30.27M 24.26M 13.54M 934.00K
Weighted Average Basic & Diluted Shares Outstanding		 31.49M 31.96M 34.07M 33.38M 34.76M 33.45M 32.95M 30.27M 24.26M 13.54M 934.00K

Quarterly Income Statements for Collegium Pharmaceutical

This table shows Collegium Pharmaceutical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 2.42 13 9.34 20 28 32 21 13 -17 -7.20 0.46
Consolidated Net Income / (Loss)		 2.42 13 9.34 20 28 32 21 13 -17 -7.20 0.46
Net Income / (Loss) Continuing Operations		 2.42 13 9.34 20 28 32 21 13 -17 -7.20 0.46
Total Pre-Tax Income 		3.12 17 16 29 37 47 29 18 -18 -7.79 1.43
Total Operating Income		 22 38 35 47 49 62 45 36 25 12 20
Total Gross Profit		 97 98 97 91 91 95 80 74 77 50 59
Total Revenue		 178 182 159 145 145 150 137 136 145 130 127
Operating Revenue		 178 182 159 145 145 150 137 136 145 130 127
Total Cost of Revenue		 80 84 63 54 53 55 56 62 67 80 68
Operating Cost of Revenue		 80 84 63 54 53 55 56 62 67 80 68
Total Operating Expenses		 76 60 62 43 42 33 35 38 53 38 38
Selling, General & Admin Expense		 76 63 62 43 42 33 35 38 53 38 38
Other Special Charges / (Income)		 -0.79 - - - - - - - - - -
Total Other Income / (Expense), net		 -19 -21 -19 -18 -13 -15 -16 -18 -42 -20 -19
Interest Expense		 21 23 23 23 17 19 21 22 45 21 19
Interest & Investment Income		 2.23 1.81 3.28 4.40 4.49 4.30 4.54 4.03 2.75 1.03 0.01
Income Tax Expense		 0.71 4.73 6.25 9.49 8.91 15 8.15 4.79 -0.13 -0.59 0.98
Basic Earnings per Share		 $0.08 $0.39 $0.29 $0.60 $0.86 $0.95 $0.61 $0.38 ($0.51) ($0.21) $0.01
Weighted Average Basic Shares Outstanding		 31.79M 32.27M 32.26M 32.43M 32.33M 33.74M 33.74M 34.62M 34.32M 33.83M 34.06M
Diluted Earnings per Share		 $0.07 $0.36 $0.27 $0.52 $0.71 $0.93 $0.53 $0.34 ($0.51) ($0.21) $0.01
Weighted Average Diluted Shares Outstanding		 32.84M 40.42M 40.16M 40.38M 41.44M 41.79M 42.06M 42.85M 34.32M 33.83M 34.57M
Weighted Average Basic & Diluted Shares Outstanding		 32.14M 31.49M 32.25M 32.21M 32.72M 31.96M 32.61M 34.73M 34.59M 34.07M 33.57M

Annual Cash Flow Statements for Collegium Pharmaceutical

This table details how cash moves in and out of Collegium Pharmaceutical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Net Change in Cash & Equivalents		 -143 64 -13 12 6.64 23 28 -35 58 94 -5.92
Net Cash From Operating Activities		 205 275 124 104 94 28 169 -67 -75 -22 -18
Net Cash From Continuing Operating Activities		 205 275 124 104 94 28 169 -67 -75 -22 -18
Net Income / (Loss) Continuing Operations		 69 48 -25 72 27 -23 -39 -75 -94 -27 -18
Consolidated Net Income / (Loss)		 69 48 -25 72 27 -23 -39 -75 -94 -27 -18
Depreciation Expense		 3.86 3.50 2.68 1.74 0.87 0.73 1.07 0.59 0.66 0.17 0.19
Amortization Expense		 169 153 145 71 70 15 110 -0.03 -0.03 -0.03 -0.03
Non-Cash Adjustments To Reconcile Net Income		 48 47 0.35 65 21 30 140 26 5.79 2.22 0.02
Changes in Operating Assets and Liabilities, net		 -85 23 1.66 -105 -24 5.42 -42 -18 13 3.34 -0.22
Net Cash From Investing Activities		 -288 -71 -574 -1.94 -374 -6.44 -24 -0.99 -2.98 -0.36 -0.01
Net Cash From Continuing Investing Activities		 -288 -71 -574 -1.94 -374 -6.44 -24 -0.99 -2.98 -0.36 -0.01
Purchase of Property, Plant & Equipment		 -1.65 -0.46 -1.62 -1.94 -5.55 -6.44 -5.48 -0.99 -0.48 -0.36 -0.01
Acquisitions		 -268 0.00 -572 0.00 -368 0.00 -19 - -2.50 0.00 0.00
Purchase of Investments		 -111 -92 0.00 0.00 - - - - - - -
Sale and/or Maturity of Investments		 93 22 0.00 0.00 - - - - - - -
Net Cash From Financing Activities		 -61 -140 437 -89 286 2.04 -117 33 136 116 12
Net Cash From Continuing Financing Activities		 -61 -140 437 -89 286 2.04 -117 33 136 116 12
Repayment of Debt		 -272 -301 -75 -50 -49 0.00 0.00 -2.67 -2.67 -1.36 -0.03
Repurchase of Common Equity		 -60 -75 -14 -48 0.00 0.00 -0.03 - - - -
Issuance of Debt		 0.00 235 518 0.00 330 0.00 10 - - 0.00 12
Issuance of Common Equity		 0.83 0.46 0.34 0.76 0.76 0.82 1.12 35 138 72 0.00
Other Financing Activities, net		 271 0.28 7.77 7.80 4.32 1.22 -128 0.67 0.44 0.52 0.01
Cash Interest Paid		 62 73 53 18 19 0.71 - 0.14 0.28 0.35 0.18
Cash Income Taxes Paid		 52 24 10 3.01 0.48 0.00 0.00 - - - -

Quarterly Cash Flow Statements for Collegium Pharmaceutical

This table details how cash moves in and out of Collegium Pharmaceutical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 20 32 -109 -56 -10 -20 -25 13 96 40 11
Net Cash From Operating Activities		 55 85 -9.00 67 62 73 74 100 28 66 43
Net Cash From Continuing Operating Activities		 55 85 -9.47 67 62 73 74 100 28 66 43
Net Income / (Loss) Continuing Operations		 2.42 13 9.34 20 28 32 21 13 -17 -7.20 0.46
Consolidated Net Income / (Loss)		 2.42 13 9.34 20 28 32 21 13 -17 -7.20 0.46
Depreciation Expense		 1.09 1.04 0.95 0.95 0.92 0.95 0.84 0.90 0.82 0.83 0.49
Amortization Expense		 57 57 41 35 36 36 38 40 40 45 40
Non-Cash Adjustments To Reconcile Net Income		 13 4.23 10 36 -2.00 -11 39 19 -0.16 -5.16 -0.21
Changes in Operating Assets and Liabilities, net		 -17 11 -71 -24 -0.58 15 -24 27 4.68 33 2.02
Net Cash From Investing Activities		 -9.68 -12 -249 -8.91 -18 -25 -3.82 -42 -0.18 -0.94 -0.11
Net Cash From Continuing Investing Activities		 -9.68 -12 -249 -8.91 -18 -25 -3.82 -42 -0.18 -0.94 -0.11
Purchase of Property, Plant & Equipment		 -0.80 -0.57 -0.24 -0.27 -0.57 -0.16 -0.07 -0.06 -0.18 -0.94 -0.11
Purchase of Investments		 -26 -27 -11 -34 -39 -41 -9.76 -42 0.00 - -
Sale and/or Maturity of Investments		 17 16 29 26 22 16 6.00 - 0.00 - -
Net Cash From Financing Activities		 -25 -41 149 -114 -54 -68 -95 -45 68 -26 -31
Net Cash From Continuing Financing Activities		 -25 -41 149 -114 -54 -68 -95 -45 68 -26 -31
Repayment of Debt		 -16 17 -165 -79 -46 -46 -46 -46 -164 -25 -25
Issuance of Common Equity		 0.51 - 0.47 - 0.36 - 0.29 - 0.17 - 0.13
Other Financing Activities, net		 -9.60 280 0.01 -0.16 -8.67 3.01 0.13 1.03 -3.89 6.82 0.04
Cash Interest Paid		 22 15 18 12 17 16 20 18 19 17 18
Cash Income Taxes Paid		 2.46 0.62 16 36 0.17 6.91 7.28 9.27 0.74 0.36 3.26

Annual Balance Sheets for Collegium Pharmaceutical

This table presents Collegium Pharmaceutical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Total Assets		 1,664 1,143 1,174 692 644 306 291 136 162 98 5.09
Total Current Assets		 482 538 420 316 278 256 238 133 159 97 4.50
Cash & Equivalents		 71 239 174 186 174 170 147 119 153 96 1.63
Restricted Cash		 25 0.00 - - - - - - - - -
Short-Term Investments		 92 72 0.00 - - - - - - - -
Accounts Receivable		 229 180 183 106 83 73 78 9.97 2.13 0.00 -
Inventories, net		 36 32 47 17 16 9.64 7.82 1.81 1.32 0.00 -
Prepaid Expenses		 30 15 17 5.88 4.84 3.11 5.12 3.01 1.91 1.19 0.53
Plant, Property, & Equipment, net		 14 16 20 19 19 12 9.27 1.83 1.04 0.74 0.51
Total Noncurrent Assets		 1,167 590 735 357 347 39 44 0.26 2.40 0.10 0.08
Goodwill		 162 134 134 0.00 336 30 44 - 2.10 0.00 -
Intangible Assets		 891 422 567 269 - - - - - - -
Noncurrent Deferred & Refundable Income Taxes		 98 26 24 78 - - - - - - -
Other Noncurrent Operating Assets		 15 7.90 6.96 7.73 8.51 9.23 0.20 0.16 0.20 0.00 -
Total Liabilities & Shareholders' Equity		 1,664 1,143 1,174 692 644 306 291 136 162 98 5.09
Total Liabilities		 1,435 948 979 489 458 219 200 31 27 13 17
Total Current Liabilities		 510 458 434 280 239 202 189 31 26 8.43 10
Short-Term Debt		 94 183 163 48 47 3.83 1.64 1.48 - 2.67 6.19
Accounts Payable		 3.93 8.69 3.49 4.19 10 6.25 12 5.68 9.11 3.54 2.21
Accrued Expenses		 411 265 267 226 181 191 175 24 8.88 2.23 1.96
Other Current Liabilities		 1.27 0.99 1.11 0.81 0.73 0.66 - - - - 0.06
Total Noncurrent Liabilities		 925 490 546 210 218 17 11 0.00 1.51 4.21 6.91
Long-Term Debt		 788 484 538 202 210 7.67 9.86 - 1.48 4.15 6.81
Noncurrent Deferred Revenue		 10 0.00 - - - - - - - - -
Other Noncurrent Operating Liabilities		 127 6.12 7.11 7.95 8.77 9.44 0.68 - 0.03 0.07 0.10
Commitments & Contingencies		 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 229 195 195 203 186 87 92 104 135 85 -89
Total Preferred & Common Equity		 229 195 195 203 186 87 92 104 135 85 -89
Preferred Stock		 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 -
Total Common Equity		 229 195 195 203 186 87 92 104 135 85 -89
Common Stock		 590 566 538 502 519 447 429 402 358 214 12
Retained Earnings		 -164 -233 -281 -256 -333 -360 -337 -298 -223 -129 -102
Treasury Stock		 -198 -137 -62 -43 - - - - - -0.00 -0.00
Accumulated Other Comprehensive Income / (Loss)		 0.06 0.01 0.00 - - - - - - - -

Quarterly Balance Sheets for Collegium Pharmaceutical

This table presents Collegium Pharmaceutical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 1,631 1,635 1,053 1,114 1,178 1,214 1,214 1,201
Total Current Assets		 528 444 510 539 537 537 498 405
Cash & Equivalents		 96 39 173 229 259 284 269 134
Restricted Cash		 20 25 - - - - - -
Short-Term Investments		 102 81 99 89 46 42 - -
Accounts Receivable		 229 228 184 175 182 167 179 195
Inventories, net		 37 38 28 31 34 26 33 65
Prepaid Expenses		 44 32 27 15 17 18 17 11
Plant, Property, & Equipment, net		 14 15 15 15 17 18 19 20
Total Noncurrent Assets		 1,090 1,177 528 560 624 659 697 776
Goodwill		 151 146 134 134 134 134 134 130
Intangible Assets		 836 947 353 387 456 493 530 610
Noncurrent Deferred & Refundable Income Taxes		 92 73 34 31 26 25 24 26
Other Noncurrent Operating Assets		 12 11 6.45 6.77 6.98 6.53 6.75 7.12
Total Liabilities & Shareholders' Equity		 1,631 1,635 1,053 1,114 1,178 1,214 1,214 1,201
Total Liabilities		 1,397 1,401 837 892 999 1,013 1,035 1,004
Total Current Liabilities		 487 459 462 446 465 435 413 414
Short-Term Debt		 89 94 183 183 183 183 183 142
Accounts Payable		 18 3.14 2.41 6.02 3.65 2.42 2.99 7.64
Accrued Expenses		 378 361 275 256 277 248 225 264
Other Current Liabilities		 1.30 1.27 1.04 1.01 0.96 0.97 1.04 1.18
Total Noncurrent Liabilities		 910 941 375 446 534 578 622 589
Long-Term Debt		 773 803 369 440 528 571 615 582
Noncurrent Deferred Revenue		 10 10 - - - - - -
Other Noncurrent Operating Liabilities		 127 129 5.59 5.86 6.38 6.63 6.87 7.35
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 234 234 217 222 179 201 180 197
Total Preferred & Common Equity		 234 234 217 222 179 201 180 197
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 234 234 217 222 179 201 180 197
Common Stock		 593 583 568 565 546 549 540 526
Retained Earnings		 -162 -177 -186 -205 -265 -286 -299 -274
Treasury Stock		 -198 -172 -165 -137 -102 -62 -62 -54
Accumulated Other Comprehensive Income / (Loss)		 0.24 0.39 -0.18 -0.12 -0.05 -0.04 - -

Annual Metrics And Ratios for Collegium Pharmaceutical

This table displays calculated financial ratios and metrics derived from Collegium Pharmaceutical's official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 11.41% 22.17% 67.56% -10.69% 4.49% 5.81% 884.73% 1,564.29% 0.00% 0.00% 0.00%
EBITDA Growth		 6.00% 79.25% 100.71% -29.04% 1,633.62% -109.16% 220.48% 19.87% -249.13% -16,831.25% 101.01%
EBIT Growth		 1.76% 401.10% 89.01% -68.65% 336.79% -14.81% 72.58% 19.81% -249.66% 0.00% 100.00%
NOPAT Growth		 12.34% 355.18% 89.01% -77.38% 428.09% -14.81% 72.58% 19.81% -249.66% 0.00% 100.00%
Net Income Growth		 43.68% 292.60% -134.96% 167.33% 217.74% 41.93% 47.74% 20.51% -245.54% 0.00% 100.00%
EPS Growth		 44.19% 274.32% -139.78% 144.74% 211.76% 42.86% 51.82% 36.34% -162.16% 93.49% -459.61%
Operating Cash Flow Growth		 -25.39% 121.16% 19.96% 10.24% 238.13% -83.60% 352.75% 10.71% -248.00% -20.17% -8.57%
Free Cash Flow Firm Growth		 -191.79% 163.31% -3,009.78% 105.25% -2,692.71% -31.06% 128.02% -6.97% -232.82% -1,774.46% 0.00%
Invested Capital Growth		 67.11% -23.28% 172.62% -0.94% 474.83% -63.24% -229.04% 21.85% -333.23% -312.34% 0.00%
Revenue Q/Q Growth		 5.37% 3.68% 28.27% -15.01% 0.67% 0.26% 28.76% 49.99% 319.36% 0.00% 0.00%
EBITDA Q/Q Growth		 -0.83% 14.63% 68.46% -36.07% 35.35% -148.44% 97.42% 39.88% -89.35% -346.59% 0.00%
EBIT Q/Q Growth		 -12.19% 42.67% 365.28% -73.59% 44.69% -128.92% 58.02% 39.88% -89.23% -351.30% 0.00%
NOPAT Q/Q Growth		 -10.94% 113.62% 365.28% -92.36% 40.34% -128.92% 58.02% 39.88% -89.23% -275.91% 0.00%
Net Income Q/Q Growth		 -21.90% 434.11% 41.63% -30.91% 52.06% -98.71% 40.37% 11.95% -16.53% -2,060.79% 0.00%
EPS Q/Q Growth		 -23.46% 760.00% 32.11% -29.01% 55.10% -106.06% 39.90% 17.11% -108.60% 78.83% 0.00%
Operating Cash Flow Q/Q Growth		 5.84% 2.62% 32.01% 15.15% 7.95% -48.94% 48.84% 12.97% -23.64% -6.79% 0.00%
Free Cash Flow Firm Q/Q Growth		 6.01% 9.69% 19.78% -91.72% 2.74% -90.04% 115.43% 37.59% -93.29% 0.00% 0.00%
Invested Capital Q/Q Growth		 -6.39% -5.52% -8.23% 3.92% -1.95% -22.40% -174.03% -42.42% -41.28% 13.44% 0.00%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 59.76% 57.55% 45.15% 54.40% 58.01% 34.73% 40.92% 90.89% 87.55% 0.00% 0.00%
EBITDA Margin		 54.33% 57.10% 38.92% 32.49% 40.89% -2.79% 32.18% -262.98% -5,462.36% 0.00% 0.00%
Operating Margin		 26.91% 29.46% 7.18% 6.37% 18.14% -8.00% -7.38% -264.95% -5,498.66% 0.00% 0.00%
EBIT Margin		 26.91% 29.46% 7.18% 6.37% 18.14% -8.00% -7.38% -264.95% -5,498.66% 0.00% 0.00%
Profit (Net Income) Margin		 10.96% 8.50% -5.39% 25.83% 8.63% -7.66% -13.95% -262.91% -5,504.15% 0.00% 0.00%
Tax Burden Percent		 70.20% 63.59% 86.67% -2,119.65% 96.99% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00%
Interest Burden Percent		 58.02% 45.36% -86.58% -19.14% 49.05% 95.68% 189.16% 99.23% 100.10% 101.29% 0.00%
Effective Tax Rate		 29.80% 36.41% 0.00% 0.00% 3.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 16.18% 16.70% 4.74% 4.65% 55.83% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 6.64% 3.53% -11.76% 88.33% 127.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 16.44% 7.98% -17.31% 32.12% -36.27% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 32.62% 24.68% -12.57% 36.77% 19.57% -25.39% -39.99% -62.65% -85.62% -74.84% 0.00%
Cash Return on Invested Capital (CROIC)		 -34.07% 43.04% -87.91% 5.60% -106.21% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 12.11% 14.41% 3.57% 2.64% 11.84% -7.95% -9.69% -50.71% -72.44% 0.00% 0.00%
Return on Assets (ROA)		 4.93% 4.16% -2.68% 10.71% 5.63% -7.61% -18.34% -50.32% -72.52% 0.00% 0.00%
Return on Common Equity (ROCE)		 32.62% 24.68% -12.57% 36.77% 19.57% -25.39% -39.99% -62.65% -85.62% 4.39% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 30.23% 24.64% -12.83% 35.24% 14.38% -25.99% -42.72% -71.93% -69.81% -32.04% 0.00%
Net Operating Profit after Tax (NOPAT)		 119 106 23 12 55 -17 -14 -53 -66 -19 0.00
NOPAT Margin		 18.89% 18.73% 5.03% 4.46% 17.59% -5.60% -5.16% -185.46% -3,849.06% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 9.53% 13.16% 16.50% -83.68% -71.17% -4.15% -19.53% -16.39% -23.52% -21.68% 0.00%
Return On Investment Capital (ROIC_SIMPLE)		 10.74% 12.31% 2.60% - - - - - - - -
Cost of Revenue to Revenue		 40.24% 42.45% 54.85% 45.60% 41.99% 65.27% 59.08% 9.11% 12.45% 0.00% 0.00%
SG&A Expenses to Revenue		 33.31% 28.09% 37.11% 42.97% 36.72% 39.25% 45.20% 325.73% 4,712.57% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.86% 3.41% 3.15% 3.49% 3.09% 30.10% 873.64% 0.00% 0.00%
Operating Expenses to Revenue		 32.85% 28.09% 37.97% 48.03% 39.87% 42.73% 48.29% 355.84% 5,586.21% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 170 167 33 18 56 -24 -21 -75 -94 -27 0.00
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 343 324 181 90 127 -8.27 90 -75 -93 -27 0.16
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.04 5.14 4.00 3.18 3.72 7.89 6.23 5.78 3.30 6.69 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 11.91 12.06 5.78 3.35 6.69 0.00
Price to Revenue (P/Rev)		 1.46 1.77 1.68 2.33 2.23 2.33 2.04 21.11 260.35 0.00 0.00
Price to Earnings (P/E)		 13.35 20.84 0.00 9.03 25.89 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 7.49% 4.80% 0.00% 11.08% 3.86% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.75 2.46 1.82 2.69 2.91 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 2.56 2.40 2.82 2.56 2.50 1.79 1.55 16.99 171.67 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 4.72 4.20 7.23 7.89 6.12 0.00 4.83 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 9.52 8.15 39.20 40.24 13.79 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 13.56 12.81 56.00 57.48 14.22 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 7.89 4.95 10.51 6.85 8.26 19.13 2.57 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 4.97 0.00 47.74 0.00 48.69 27.52 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 3.85 3.41 3.60 1.23 1.38 0.13 0.13 0.01 0.01 0.08 -1.06
Long-Term Debt to Equity		 3.44 2.48 2.76 0.99 1.13 0.09 0.11 0.00 0.01 0.05 -0.56
Financial Leverage		 2.48 2.26 1.47 0.36 -0.29 -1.64 -1.29 -1.13 -1.09 -1.07 -0.92
Leverage Ratio		 6.62 5.94 4.69 3.43 3.47 3.34 2.18 1.25 1.18 1.41 -0.42
Compound Leverage Factor		 3.84 2.69 -4.06 -0.66 1.70 3.19 4.13 1.24 1.18 1.43 0.00
Debt to Total Capital		 79.39% 77.34% 78.25% 55.19% 58.02% 11.62% 11.16% 1.40% 1.08% 7.41% 1,698.04%
Short-Term Debt to Total Capital		 8.42% 21.25% 18.14% 10.68% 10.72% 3.87% 1.59% 1.40% 0.00% 2.90% 808.62%
Long-Term Debt to Total Capital		 70.96% 56.09% 60.11% 44.52% 47.30% 7.75% 9.56% 0.00% 1.08% 4.51% 889.43%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 10,066.19%
Common Equity to Total Capital		 20.61% 22.66% 21.75% 44.81% 41.98% 88.38% 88.84% 98.60% 98.92% 92.59% -11,664.23%
Debt to EBITDA		 2.57 2.06 3.88 2.78 2.03 -1.39 0.13 -0.02 -0.02 -0.25 81.29
Net Debt to EBITDA		 2.02 1.10 2.92 0.71 0.65 19.18 -1.50 1.57 1.62 3.32 71.08
Long-Term Debt to EBITDA		 2.30 1.50 2.98 2.24 1.65 -0.93 0.11 0.00 -0.02 -0.15 42.58
Debt to NOPAT		 7.39 6.28 30.05 20.26 4.71 -0.69 -0.79 -0.03 -0.02 -0.36 0.00
Net Debt to NOPAT		 5.82 3.36 22.61 5.15 1.52 9.54 9.33 2.22 2.30 4.72 0.00
Long-Term Debt to NOPAT		 6.61 4.56 23.09 16.34 3.84 -0.46 -0.68 0.00 -0.02 -0.22 0.00
Altman Z-Score		 0.95 1.41 0.62 0.82 1.02 1.17 1.02 7.65 7.01 25.32 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 105.87% -629.91%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.95 1.17 0.97 1.13 1.16 1.27 1.26 4.24 6.20 11.49 0.43
Quick Ratio		 0.77 1.07 0.82 1.05 1.08 1.20 1.19 4.09 6.07 11.35 0.16
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -251 274 -432 15 -283 11 16 -57 -53 -16 0.95
Operating Cash Flow to CapEx		 12,407.99% 59,598.48% 7,659.06% 5,327.01% 1,693.87% 431.55% 3,092.75% -6,769.49% -15,734.38% -5,957.73% -224,337.50%
Free Cash Flow to Firm to Interest Expense		 -2.94 2.56 -6.84 0.71 -9.80 12.01 0.79 0.00 -562.04 0.00 0.00
Operating Cash Flow to Interest Expense		 2.40 2.57 1.97 4.93 3.25 30.56 8.41 0.00 -798.44 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 2.38 2.57 1.94 4.84 3.06 23.48 8.14 0.00 -803.51 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.45 0.49 0.50 0.41 0.65 0.99 1.31 0.19 0.01 0.00 0.00
Accounts Receivable Turnover		 3.09 3.13 3.21 2.93 3.97 3.93 6.38 4.71 0.00 0.00 0.00
Inventory Turnover		 7.49 6.10 7.96 7.65 10.31 22.18 34.41 1.66 0.00 0.00 0.00
Fixed Asset Turnover		 41.66 31.93 23.78 14.39 20.10 28.09 50.52 19.89 1.93 0.00 0.00
Accounts Payable Turnover		 40.25 39.49 66.24 17.78 16.01 21.05 18.58 0.35 0.03 0.00 0.00
Days Sales Outstanding (DSO)		 117.94 116.77 113.67 124.69 91.99 92.82 57.22 77.53 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 48.76 59.80 45.83 47.71 35.41 16.45 10.61 220.05 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 9.07 9.24 5.51 20.53 22.80 17.34 19.64 1,040.14 10,832.62 0.00 0.00
Cash Conversion Cycle (CCC)		 157.63 167.33 153.99 151.87 104.60 91.93 48.18 -742.55 -10,832.62 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 923 552 720 264 266 -71 -44 -13 -17 -3.91 -0.95
Invested Capital Turnover		 0.86 0.89 0.94 1.04 3.17 -5.18 -9.88 -1.89 -0.16 0.00 0.00
Increase / (Decrease) in Invested Capital		 370 -168 456 -2.52 338 -28 -30 3.70 -13 -2.96 -0.95
Enterprise Value (EV)		 1,618 1,360 1,306 709 776 531 436 484 294 480 0.00
Market Capitalization		 924 1,004 779 646 693 690 571 601 445 569 0.00
Book Value per Share		 $7.10 $5.99 $5.80 $5.87 $5.38 $2.61 $2.75 $3.20 $4.72 $4.11 ($95.66)
Tangible Book Value per Share		 ($25.58) ($11.04) ($15.08) ($1.90) ($4.33) $1.73 $1.42 $3.20 $4.64 $4.11 ($95.66)
Total Capital		 1,110 863 896 453 443 99 103 106 136 92 0.77
Total Debt		 881 667 701 250 257 12 12 1.48 1.48 6.81 13
Total Long-Term Debt		 788 484 538 202 210 7.67 9.86 0.00 1.48 4.15 6.81
Net Debt		 694 357 527 64 83 -159 -135 -117 -152 -89 11
Capital Expenditures (CapEx)		 1.65 0.46 1.62 1.94 5.55 6.44 5.48 0.99 0.48 0.36 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -121 -48 -25 -102 -88 -112 -97 -15 -20 -4.58 -1.36
Debt-free Net Working Capital (DFNWC)		 66 263 149 84 86 58 50 103 133 91 0.27
Net Working Capital (NWC)		 -27 80 -14 36 38 54 48 102 133 88 -5.92
Net Nonoperating Expense (NNE)		 50 58 48 -59 28 6.10 25 22 28 8.42 0.00
Net Nonoperating Obligations (NNO)		 694 357 525 61 80 -159 -135 -117 -152 -89 11
Total Depreciation and Amortization (D&A)		 173 157 147 72 71 15 111 0.56 0.62 0.14 0.16
Debt-free, Cash-free Net Working Capital to Revenue		 -19.24% -8.39% -5.37% -36.88% -28.45% -37.83% -34.45% -53.46% -1,183.28% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 10.50% 46.41% 32.07% 30.46% 27.72% 19.48% 17.84% 363.38% 7,772.00% 0.00% 0.00%
Net Working Capital to Revenue		 -4.32% 14.06% -2.96% 12.99% 12.40% 18.19% 17.26% 358.18% 7,772.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $2.14 $1.43 $0.00 $0.00 $0.00 ($0.68) ($1.19) ($2.47) ($3.88) ($1.48) ($22.72)
Adjusted Weighted Average Basic Shares Outstanding		 32.27M 33.74M 0.00 0.00 0.00 34.05M 33.31M 32.99M 29.45M 23.51M 934.00K
Adjusted Diluted Earnings per Share		 $1.86 $1.29 $0.00 $0.00 $0.00 ($0.68) ($1.19) ($2.47) ($94,176,000.00) ($1.48) ($22.72)
Adjusted Weighted Average Diluted Shares Outstanding		 40.42M 41.79M 0.00 0.00 0.00 34.05M 33.31M 32.99M 29.45M 23.51M 934.00K
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 ($0.68) ($1.19) ($2.47) ($94,176,000.00) ($1.48) ($22.72)
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 31.49M 31.96M 0.00 0.00 0.00 33.45M 32.95M 30.27M 24.26M 13.54M 934.00K
Normalized Net Operating Profit after Tax (NOPAT)		 117 106 23 16 55 -17 -14 -53 -66 -19 0.00
Normalized NOPAT Margin		 18.56% 18.73% 5.03% 5.61% 17.59% -5.60% -5.16% -185.46% -3,849.06% 0.00% 0.00%
Pre Tax Income Margin		 15.61% 13.36% -6.22% -1.22% 8.90% -7.66% -13.95% -262.91% -5,504.15% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 1.99 1.56 0.53 0.84 1.95 -26.13 -1.03 0.00 -1,000.87 0.00 0.00
NOPAT to Interest Expense		 1.40 0.99 0.37 0.59 1.89 -18.29 -0.72 0.00 -700.61 0.00 0.00
EBIT Less CapEx to Interest Expense		 1.97 1.56 0.50 0.75 1.75 -33.21 -1.30 0.00 -1,005.95 0.00 0.00
NOPAT Less CapEx to Interest Expense		 1.38 0.99 0.34 0.49 1.70 -25.37 -0.99 0.00 -705.69 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 86.75% 155.75% -56.25% 66.92% 0.00% 0.00% -0.08% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Collegium Pharmaceutical

This table displays calculated financial ratios and metrics derived from Collegium Pharmaceutical's official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 22.66% 21.51% 16.53% 7.18% 0.11% 15.53% 7.63% 9.71% 72.85% 373.72% 61.10%
EBITDA Growth		 -8.09% -2.92% -7.69% 10.07% 32.33% 72.15% 37.30% 47.05% 518.80% 455.02% 89.21%
EBIT Growth		 -56.16% -38.22% -22.60% 33.22% 100.89% 424.69% 119.93% 220.73% 345.90% 134.46% 44.65%
NOPAT Growth		 -55.15% -34.41% -35.31% 22.82% 117.17% 412.54% 394.04% 234.87% 345.90% 134.46% -48.15%
Net Income Growth		 -91.28% -60.75% -54.76% 50.73% 259.03% 543.67% 4,415.10% 350.57% -33.34% 71.24% -94.32%
EPS Growth		 -90.14% -61.29% -49.06% 52.94% 239.22% 542.86% 5,200.00% 326.67% -30.77% 62.50% -95.45%
Operating Cash Flow Growth		 -10.56% 15.42% -112.16% -32.41% 123.83% 10.57% 73.06% 146.53% 209.31% 83.23% 147.88%
Free Cash Flow Firm Growth		 -254.69% -263.48% -263.89% -23.74% 30.40% 146.87% 144.32% 144.01% 128.11% -1,993.69% -1,823.90%
Invested Capital Growth		 67.06% 67.11% 68.66% -21.03% -25.47% -23.28% -25.48% -23.14% -17.46% 172.62% 208.72%
Revenue Q/Q Growth		 -2.30% 14.22% 9.65% 0.24% -3.22% 9.54% 0.86% -6.37% 11.69% 2.05% 2.80%
EBITDA Q/Q Growth		 -17.12% 23.80% -7.80% -2.84% -12.45% 17.71% 9.94% 16.81% 13.89% -6.12% 17.74%
EBIT Q/Q Growth		 -43.10% 9.39% -26.61% -4.05% -19.80% 37.04% 26.32% 44.69% 109.47% -42.56% 84.22%
NOPAT Q/Q Growth		 -39.31% 32.53% -34.74% -14.56% -11.25% 30.72% 23.91% 51.07% 109.47% 26.00% -16.01%
Net Income Q/Q Growth		 -80.72% 34.29% -52.39% -29.25% -13.23% 54.79% 58.64% 174.64% -142.06% -1,675.27% 108.80%
EPS Q/Q Growth		 -80.56% 33.33% -48.08% -26.76% -23.66% 75.47% 55.88% 166.67% -142.86% -2,200.00% 106.67%
Operating Cash Flow Q/Q Growth		 -34.55% 1,040.59% -113.35% 8.82% -15.55% -0.92% -25.78% 260.38% -58.28% 55.08% 5.73%
Free Cash Flow Firm Q/Q Growth		 1.96% 9.86% -331.48% -24.39% 3.11% -9.64% 7.71% 29.31% 137.24% 14.55% -6.95%
Invested Capital Q/Q Growth		 -4.71% -6.39% 98.39% -5.60% -4.50% -5.52% -7.11% -10.90% -1.88% -8.23% -4.20%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 54.75% 54.02% 60.76% 62.51% 63.11% 63.19% 58.75% 54.47% 53.47% 38.41% 46.33%
EBITDA Margin		 44.61% 52.58% 48.51% 57.70% 59.53% 65.81% 61.24% 56.18% 45.04% 44.16% 48.01%
Operating Margin		 12.20% 20.95% 21.87% 32.68% 34.14% 41.20% 32.93% 26.29% 17.01% 9.07% 16.11%
EBIT Margin		 12.20% 20.95% 21.87% 32.68% 34.14% 41.20% 32.93% 26.29% 17.01% 9.07% 16.11%
Profit (Net Income) Margin		 1.36% 6.89% 5.86% 13.50% 19.12% 21.33% 15.09% 9.60% -12.04% -5.55% 0.36%
Tax Burden Percent		 77.42% 72.59% 59.92% 67.38% 75.67% 68.38% 71.69% 73.09% 99.25% 92.40% 31.91%
Interest Burden Percent		 14.40% 45.31% 44.72% 61.29% 74.02% 75.72% 63.94% 49.95% -71.29% -66.27% 7.00%
Effective Tax Rate		 22.58% 27.41% 40.08% 32.62% 24.33% 31.62% 28.31% 26.91% 0.00% 0.00% 68.09%
Return on Invested Capital (ROIC)		 8.93% 13.02% 10.00% 22.56% 23.77% 25.11% 18.86% 14.25% 8.01% 5.99% 3.58%
ROIC Less NNEP Spread (ROIC-NNEP)		 5.90% 10.14% 8.01% 19.06% 21.43% 22.79% 16.51% 11.77% 2.16% 0.72% 1.46%
Return on Net Nonoperating Assets (RNNOA)		 12.26% 25.11% 22.42% 32.35% 44.27% 51.46% 43.57% 30.99% 6.81% 1.06% 1.79%
Return on Equity (ROE)		 21.19% 38.13% 32.43% 54.91% 68.04% 76.57% 62.43% 45.24% 14.82% 7.05% 5.38%
Cash Return on Invested Capital (CROIC)		 -36.58% -34.07% -34.05% 49.10% 51.55% 43.04% 36.46% 35.12% 25.23% -87.91% -103.83%
Operating Return on Assets (OROA)		 5.90% 9.42% 9.32% 16.62% 16.62% 20.15% 15.13% 11.48% 7.26% 4.51% 6.00%
Return on Assets (ROA)		 0.66% 3.10% 2.50% 6.86% 9.31% 10.43% 6.94% 4.19% -5.14% -2.76% 0.13%
Return on Common Equity (ROCE)		 21.19% 38.13% 32.43% 54.91% 68.04% 76.57% 62.43% 45.24% 14.82% 7.05% 5.38%
Return on Equity Simple (ROE_SIMPLE)		 18.72% 0.00% 37.82% 46.12% 41.99% 0.00% 5.04% -5.56% -16.33% 0.00% -21.72%
Net Operating Profit after Tax (NOPAT)		 17 28 21 32 37 42 32 26 17 8.23 6.53
NOPAT Margin		 9.45% 15.21% 13.10% 22.02% 25.83% 28.17% 23.60% 19.21% 11.91% 6.35% 5.14%
Net Nonoperating Expense Percent (NNEP)		 3.03% 2.88% 2.00% 3.50% 2.34% 2.32% 2.35% 2.49% 5.85% 5.27% 2.12%
Return On Investment Capital (ROIC_SIMPLE)		 1.53% 2.49% - - - 4.89% - - - 0.92% -
Cost of Revenue to Revenue		 45.25% 45.98% 39.24% 37.49% 36.89% 36.81% 41.25% 45.53% 46.53% 61.59% 53.67%
SG&A Expenses to Revenue		 42.99% 34.68% 38.89% 29.83% 28.97% 22.00% 25.82% 28.18% 36.46% 29.34% 30.21%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 42.55% 33.07% 38.89% 29.83% 28.97% 22.00% 25.82% 28.18% 36.46% 29.34% 30.21%
Earnings before Interest and Taxes (EBIT)		 22 38 35 47 49 62 45 36 25 12 20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 79 96 77 84 86 99 84 76 65 57 61
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.01 4.04 5.31 4.86 5.70 5.14 4.34 3.70 4.55 4.00 2.77
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 1.41 1.46 2.08 1.83 2.23 1.77 1.42 1.38 1.56 1.68 1.51
Price to Earnings (P/E)		 21.41 13.35 14.05 10.55 13.57 20.84 86.10 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 4.67% 7.49% 7.12% 9.48% 7.37% 4.80% 1.16% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.80 1.75 2.03 2.69 2.99 2.46 2.02 1.86 1.91 1.82 1.45
Enterprise Value to Revenue (EV/Rev)		 2.39 2.56 3.33 2.31 2.77 2.40 2.16 2.18 2.56 2.82 3.14
Enterprise Value to EBITDA (EV/EBITDA)		 4.71 4.72 5.77 3.79 4.56 4.20 4.19 4.52 5.72 7.23 10.60
Enterprise Value to EBIT (EV/EBIT)		 11.15 9.52 10.32 6.55 8.19 8.15 10.11 12.68 19.81 39.20 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 16.53 13.56 14.91 9.26 11.41 12.81 23.80 18.11 28.30 56.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 7.98 7.89 10.31 4.82 5.08 4.95 4.42 4.96 7.60 10.51 12.07
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 4.83 4.95 4.97 4.74 4.61 6.83 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 3.68 3.85 3.83 2.55 2.80 3.41 3.98 3.76 4.44 3.60 3.67
Long-Term Debt to Equity		 3.30 3.44 3.43 1.71 1.98 2.48 2.95 2.85 3.42 2.76 2.95
Financial Leverage		 2.08 2.48 2.80 1.70 2.07 2.26 2.64 2.63 3.15 1.47 1.23
Leverage Ratio		 6.01 6.62 6.81 5.43 5.79 5.94 6.32 6.17 6.55 4.69 4.17
Compound Leverage Factor		 0.87 3.00 3.04 3.33 4.29 4.50 4.04 3.08 -4.67 -3.11 0.29
Debt to Total Capital		 78.62% 79.39% 79.28% 71.85% 73.72% 77.34% 79.90% 78.99% 81.62% 78.25% 78.58%
Short-Term Debt to Total Capital		 8.13% 8.42% 8.27% 23.83% 21.69% 21.25% 20.60% 19.19% 18.74% 18.14% 15.39%
Long-Term Debt to Total Capital		 70.50% 70.96% 71.00% 48.02% 52.03% 56.09% 59.30% 59.80% 62.88% 60.11% 63.20%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 21.38% 20.61% 20.72% 28.15% 26.28% 22.66% 20.10% 21.01% 18.38% 21.75% 21.42%
Debt to EBITDA		 2.57 2.57 2.59 1.57 1.81 2.06 2.52 2.91 3.39 3.88 6.75
Net Debt to EBITDA		 1.92 2.02 2.17 0.80 0.89 1.10 1.44 1.65 2.25 2.92 5.50
Long-Term Debt to EBITDA		 2.30 2.30 2.32 1.05 1.28 1.50 1.87 2.20 2.61 2.98 5.43
Debt to NOPAT		 8.99 7.39 6.69 3.84 4.52 6.28 14.31 11.66 16.78 30.05 -82.30
Net Debt to NOPAT		 6.72 5.82 5.61 1.95 2.21 3.36 8.18 6.63 11.12 22.61 -67.04
Long-Term Debt to NOPAT		 8.06 6.61 5.99 2.56 3.19 4.56 10.62 8.83 12.93 23.09 -66.19
Altman Z-Score		 0.75 0.68 0.81 1.26 1.35 1.11 0.82 0.75 0.71 0.56 0.36
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.08 0.95 0.97 1.11 1.21 1.17 1.16 1.24 1.21 0.97 0.98
Quick Ratio		 0.88 0.77 0.76 0.99 1.10 1.07 1.05 1.13 1.09 0.82 0.80
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -336 -343 -380 164 217 210 232 215 167 -447 -524
Operating Cash Flow to CapEx		 6,942.11% 14,849.82% -3,688.11% 24,962.22% 10,904.40% 44,718.29% 113,873.85% 178,075.00% 15,722.16% 7,055.85% 37,848.67%
Free Cash Flow to Firm to Interest Expense		 -16.17 -15.13 -16.87 7.22 12.53 10.88 11.17 9.85 3.71 -21.74 -27.49
Operating Cash Flow to Interest Expense		 2.66 3.74 -0.40 2.96 3.57 3.80 3.56 4.56 0.62 3.22 2.25
Operating Cash Flow Less CapEx to Interest Expense		 2.63 3.71 -0.41 2.95 3.54 3.80 3.56 4.56 0.61 3.18 2.24
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.48 0.45 0.43 0.51 0.49 0.49 0.46 0.44 0.43 0.50 0.37
Accounts Receivable Turnover		 3.29 3.09 2.92 3.28 3.20 3.13 2.90 2.94 3.04 3.21 2.10
Inventory Turnover		 8.21 7.49 6.25 8.14 7.07 6.10 5.37 5.34 5.07 7.96 4.96
Fixed Asset Turnover		 45.33 41.66 38.34 34.93 33.02 31.93 30.04 28.26 26.86 23.78 18.37
Accounts Payable Turnover		 23.55 40.25 66.39 90.83 50.31 39.49 47.00 61.26 83.75 66.24 26.46
Days Sales Outstanding (DSO)		 110.83 117.94 124.96 111.19 113.90 116.77 125.95 124.05 120.10 113.67 173.78
Days Inventory Outstanding (DIO)		 44.47 48.76 58.38 44.81 51.66 59.80 67.95 68.36 71.99 45.83 73.62
Days Payable Outstanding (DPO)		 15.50 9.07 5.50 4.02 7.25 9.24 7.77 5.96 4.36 5.51 13.79
Cash Conversion Cycle (CCC)		 139.80 157.63 177.84 151.99 158.30 167.33 186.13 186.46 187.74 153.99 233.61
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 879 923 985 497 526 552 584 629 706 720 784
Invested Capital Turnover		 0.95 0.86 0.76 1.02 0.92 0.89 0.80 0.74 0.67 0.94 0.70
Increase / (Decrease) in Invested Capital		 353 370 401 -132 -180 -168 -200 -189 -149 456 530
Enterprise Value (EV)		 1,584 1,618 1,996 1,335 1,571 1,360 1,183 1,173 1,346 1,306 1,136
Market Capitalization		 940 924 1,245 1,053 1,266 1,004 776 743 817 779 547
Book Value per Share		 $7.45 $7.10 $7.27 $6.62 $6.87 $5.99 $5.15 $5.80 $5.28 $5.80 $5.78
Tangible Book Value per Share		 ($23.89) ($25.58) ($26.65) ($8.25) ($9.25) ($11.04) ($11.84) ($12.30) ($14.21) ($15.08) ($15.90)
Total Capital		 1,097 1,110 1,130 769 845 863 890 956 978 896 921
Total Debt		 862 881 896 553 623 667 711 755 798 701 724
Total Long-Term Debt		 773 788 803 369 440 484 528 571 615 538 582
Net Debt		 645 694 751 281 305 357 406 429 529 527 589
Capital Expenditures (CapEx)		 0.80 0.57 0.24 0.27 0.57 0.16 0.07 0.06 0.18 0.94 0.11
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -88 -121 -67 -40 -42 -48 -49 -40 -0.55 -25 -1.74
Debt-free Net Working Capital (DFNWC)		 130 66 78 232 276 263 256 286 269 149 132
Net Working Capital (NWC)		 41 -27 -16 48 93 80 72 102 86 -14 -9.28
Net Nonoperating Expense (NNE)		 14 15 12 12 9.73 10 12 13 35 15 6.07
Net Nonoperating Obligations (NNO)		 645 694 751 280 304 357 405 428 526 525 587
Total Depreciation and Amortization (D&A)		 58 58 42 36 37 37 39 41 41 45 41
Debt-free, Cash-free Net Working Capital to Revenue		 -13.19% -19.24% -11.19% -6.90% -7.39% -8.39% -8.92% -7.43% -0.10% -5.37% -0.48%
Debt-free Net Working Capital to Revenue		 19.57% 10.50% 13.00% 40.20% 48.71% 46.41% 46.80% 53.18% 51.23% 32.07% 36.60%
Net Working Capital to Revenue		 6.15% -4.32% -2.61% 8.41% 16.37% 14.06% 13.26% 19.04% 16.31% -2.96% -2.57%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.08 $0.39 $0.29 $0.60 $0.86 $0.95 $0.61 $0.38 ($0.51) ($0.21) $0.01
Adjusted Weighted Average Basic Shares Outstanding		 31.79M 32.27M 32.26M 32.43M 32.33M 33.74M 33.74M 34.62M 34.32M 33.83M 34.06M
Adjusted Diluted Earnings per Share		 $0.07 $0.36 $0.27 $0.52 $0.71 $0.93 $0.53 $0.34 ($0.51) ($0.21) $0.01
Adjusted Weighted Average Diluted Shares Outstanding		 32.84M 40.42M 40.16M 40.38M 41.44M 41.79M 42.06M 42.85M 34.32M 33.83M 34.57M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 32.14M 31.49M 32.25M 32.21M 32.72M 31.96M 32.61M 34.73M 34.59M 34.07M 33.57M
Normalized Net Operating Profit after Tax (NOPAT)		 16 28 21 32 37 42 32 26 17 8.23 14
Normalized NOPAT Margin		 9.10% 15.21% 13.10% 22.02% 25.83% 28.17% 23.60% 19.21% 11.91% 6.35% 11.28%
Pre Tax Income Margin		 1.76% 9.49% 9.78% 20.03% 25.27% 31.19% 21.05% 13.13% -12.13% -6.01% 1.13%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 1.04 1.68 1.55 2.08 2.85 3.20 2.17 1.63 0.55 0.57 1.07
NOPAT to Interest Expense		 0.81 1.22 0.93 1.40 2.16 2.19 1.55 1.19 0.38 0.40 0.34
EBIT Less CapEx to Interest Expense		 1.00 1.66 1.53 2.07 2.82 3.19 2.16 1.63 0.54 0.53 1.07
NOPAT Less CapEx to Interest Expense		 0.77 1.20 0.92 1.39 2.13 2.18 1.55 1.19 0.38 0.35 0.34
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 86.75% 67.72% 110.12% 80.39% 155.75% 639.32% -126.00% -47.90% -56.25% -90.48%

Frequently Asked Questions About Collegium Pharmaceutical's Financials

When does Collegium Pharmaceutical's fiscal year end?

According to the most recent income statement we have on file, Collegium Pharmaceutical's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Collegium Pharmaceutical's net income changed over the last 10 years?

Collegium Pharmaceutical's net income appears to be on a downward trend, with a most recent value of $69.19 million in 2024, rising from $0.00 in 2014. The previous period was $48.16 million in 2023. Find out what analysts predict for Collegium Pharmaceutical in the coming months.

What is Collegium Pharmaceutical's operating income?
Collegium Pharmaceutical's total operating income in 2024 was $169.90 million, based on the following breakdown:
  • Total Gross Profit: $377.34 million
  • Total Operating Expenses: $207.45 million
How has Collegium Pharmaceutical revenue changed over the last 10 years?

Over the last 10 years, Collegium Pharmaceutical's total revenue changed from $0.00 in 2014 to $631.45 million in 2024, a change of 63,144,900,000.0%.

How much debt does Collegium Pharmaceutical have?

Collegium Pharmaceutical's total liabilities were at $1.43 billion at the end of 2024, a 51.4% increase from 2023, and a 8,178.5% increase since 2014.

How much cash does Collegium Pharmaceutical have?

In the past 10 years, Collegium Pharmaceutical's cash and equivalents has ranged from $1.63 million in 2014 to $238.95 million in 2023, and is currently $70.57 million as of their latest financial filing in 2024.

How has Collegium Pharmaceutical's book value per share changed over the last 10 years?

Over the last 10 years, Collegium Pharmaceutical's book value per share changed from -95.66 in 2014 to 7.10 in 2024, a change of -107.4%.


Related Companies

This page (NASDAQ:COLL) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners
Buffett’s Next Move Could Shock Wall Street
In just a few weeks, a move decades in the making could be revealed — and when it is, it could ignite the next...
Golden Portfolio | Sponsored
Elon Musk’s Frightening Warning Forces Trump’s Hand
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...
American Hartford Gold | Sponsored
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...
Investors Alley | Sponsored
Urgent: Make this trade before you hit your pillow tonight…
Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...
Timothy Sykes | Sponsored
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
AI Meltdown Imminent: Dump These Stocks Now!
If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...
Paradigm Press | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored